AstraZeneca Voydeya approved in EU as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia Ruchika Sharma26 April 2024 4:10 PM ISTAstraZeneca has announced that Voydeya (danicopan) has been approved in the European Union (EU) as an add-on to ravulizumab or...
USFDA nod to Voydeya as add on therapy to ravulizumab or eculizumab for extravascular haemolysis in adults with rare disease PNH: AstraZeneca Ruchika Sharma1 April 2024 3:18 PM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the...
AstraZeneca Ultomiris gets USFDA approval for adults with neuromyelitis optica spectrum disorder Ruchika Sharma26 March 2024 12:52 PM ISTUltomiris, a long-acting C5 complement inhibitor, provides immediate, complete and sustained complement inhibition.
AstraZeneca blood disorder drug recommended for EU nod Ruchika Sharma27 Feb 2024 11:29 AM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an...
Enhance risk evaluation for Rare Inflammatory Disease drug: USFDA asks AstraZeneca Ruchika Sharma6 Sept 2023 2:30 PM ISTCambridge: The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License...
AstraZeneca Ultomiris gets Japanese nod for prevention of relapses in patients with neuromyelitis optica spectrum disorder Ruchika Sharma28 May 2023 11:00 AM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AtraZeneca's Ultomiris approved in EU for adults with neuromyelitis optica spectrum disorder Ruchika Sharma12 May 2023 1:30 PM ISTNeuromyelitis optica spectrum disorder is a rare and debilitating autoimmune disease that affects the central nervous system including the spine and...
AstraZeneca Ultomiris recommended for marketing approval in EU for neuromyelitis optica spectrum disorder Ruchika Sharma4 April 2023 4:00 PM ISTNMOSD is a rare and debilitating autoimmune disease that affects the central nervous system, including the spine and optic nerves.
AstraZeneca Ultomiris approved in Europe for treatment of adults with generalised myasthenia gravis Ruchika Sharma25 Sept 2022 12:00 PM ISTUltomiris (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete and sustained complement inhibition.
AstraZeneca gets Japenese nod for Ultomiris to treat generalised myasthenia gravis Ruchika Sharma29 Aug 2022 9:30 AM ISTgMG is a rare, debilitating, chronic, autoimmune neuromuscular disease that leads to a loss of muscle function and severe weakness.
AstraZeneca arm halts trial on neurological disorder treatment Ruchika Sharma22 Aug 2021 9:15 AM ISTNew Delhi: AstraZeneca's Alexion division will stop developing a treatment for the neurological disorder ALS due to lack of efficacy in a late-stage...
AstraZeneca to acquire Alexion in USD 39 billion deal to expand immunology Ruchika Sharma14 Dec 2020 1:15 PM ISTFrankfurt: Britain's AstraZeneca has agreed to buy U.S. drugmaker Alexion Pharmaceuticals for $39 billion in its largest ever deal, diversifying away...
